Search

As an oral multi-kinase inhibitor, Sorafenib is widely used for the treatment of advanced renal cell and hepatocellular carcinoma. Skin toxicity is the most common adverse reactions of Sorafenib and may significantly affect the quality of life of patients, resulting in dose reduction or discontinuation of therapy, which will reduce the long-term benefit of the regimen. Hence appropriate recognition of its cutaneous adverse events is of particular importance to ensure proper administration of Sorafenib. This article mainly reviews the cutaneous adverse reactions induced by Sorafenib and corresponding counter measures, as well as the mechanism, clinical manifestations and the influence of adverse reactions on the prognosis of patients. [ABSTRACT FROM AUTHOR]